SCHEMBL6979305

SCHEMBL6979305

CC(C)c1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
KDM4E B2RXH2 5/20 0.55
HSD17B10 Q99714 4/20 0.55
TSHR P16473 3/20 0.55
TP53 P04637 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
NOTUM Q6P988 1/20 0.55
ALDH1A1 P00352 4/20 0.54
HPGD P15428 4/20 0.54
NFKB1 P19838 1/20 0.49
CASP3 P42574 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
MAPT P10636 2/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12126066 0.87 NOTUM (0.53) NPC1RAB9AKDM4EHSD17B10TP53
SCHEMBL9030565 0.83 NPC1 (0.56) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL11965504 0.83 NPC1 (0.58) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL15271333 0.81 DGAT1 (0.55) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL17516265 0.81 NPC1 (0.64) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL823534 0.81 ALDH1A1 (0.65) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL21887193 0.80 NPC1 (0.79) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL26288191 0.79 PKM (0.63) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL26413938 0.79 PTGS2 (0.49) NPC1RAB9AKDM4EHSD17B10TSHR
SCHEMBL24722900 0.79 NPC1 (0.62) NPC1RAB9AKDM4EHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024031041-A2 OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-02-08 WO disclosed
US-9809545-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-9809545-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-20160046581-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-02-18 US disclosed
US-8183276-B2 Therapeutic agents MERCK SHARP & DOHME CORP. 2012-05-22 US disclosed
US-20100324029-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME CORP. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046581-A1 Factor XIa Inhibitors F11, F12, TFPI NPC1 1452/4885RAB9A 1677/4885KDM4E 1035/4885
US-20100324029-A1 THERAPEUTIC AGENTS PSEN2, PSEN1, BACE2 NPC1 144/4885RAB9A 2575/4885KDM4E 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.